Letter by Taqueti and Bhatt Regarding Article, “Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with interest the study by Resor et al1 evaluating the impact of optimal medical therapy (OMT) in the DAPT study (Dual Antiplatelet Therapy), which demonstrated that thienopyridine therapy extended between 12 and 30 months in patients after coronary artery stenting resulted in lower rates of myocardial infarction, major adverse cardiovascular and cerebrovascular events, and bleeding events in patients on compared with off OMT. As the authors note, although the associations with lower rates of myocardial infarction and major adverse cardiovascular and cerebrovascular events were expected, the association with bleeding was not.
The authors should be commended for evaluating the impact of OMT on the treatment effect—both ischemic and …